Fundz

CereVasc Announces Closing of $43.9 Million Series A Financing

PRIVATEJun 09, 2020

Amount Raised

$43 Million

Round Type

Series A

BostonBiotechnology

Description

CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the closing of an expanded Series A financing that raised a total of $43.9 million led by the Perceptive Xontogeny Venture (PXV) Fund and ATON Partners, LLC.

Who else raised in Biotechnology around the same time

Companies in the same sectors as CereVasc that raised within 45 days of this round, from Fundz verified event records.

  • Azure Health Technology Ltd raised $353K (Seed) on July 24, 2020.
  • Elucidata raised $880K on July 23, 2020.
  • Tasso raised $17M on July 23, 2020.
  • TriFlo Cardiovascular Inc raised $4.6M (Seed) on July 22, 2020.
  • Nanoscope Therapeutics raised $13M on July 22, 2020.
  • Revalesio raised $20M on July 22, 2020.

Who to call at CereVasc, and when

A new round usually means CereVasc is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day CereVasc raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at CereVasc, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at CereVasc. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

CereVasc

Location

2120 COMMONWEALTH AVE., SUITE 1

Boston, Massachusetts, United States

About

Located in Massachusetts’ healthcare hub, CereVasc, Inc., is a clinical stage, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, encompasses first-ever, groundbreaking percutaneous transvenous-transdural access to the central nervous system intended to allow the first minimally invasive treatment for communicating hydrocephalus (CH), a potential improvement to the current standard of care. The eShunt device concept originated from Tufts Medical Center physicians Carl Heilman, MD, Neurosurgeon-in-Chief and Chair of Neurosurgery, and Adel Malek, MD, PhD, Chief of Neurovascular Surgery and Director of Endovascular Neurosurgery. The patented eShunt System includes an endovascularly implantable cerebral spinal fluid shunt and delivery components, which are designed to treat CH without invasive surgery.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment CereVasc raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsTiffany W., Senior Director, Marketing & Communicat… hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for CereVasc's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

CereVasc raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.